Recent Finacing
Recent Raise
ITBMed is a Stockholm biopharmaceutical developing immunomodulatory biologics for organ and stem-cell transplantation, advancing monoclonal antibody Siplizumab in late-stage trials and preclinical R&D with Columbia University.